Paper33476708
Furin is not required for processing of mesothelin precursor protein.
Joseph S and 3 others. Biochim Biophys Acta Mol Cell Res, 2021. Cited by 6 papers, by iCite.
Cite this record
ConductScience Library. Furin is not required for processing of mesothelin precursor protein. Papers, record 33476708. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/33476708
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics10
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Furin | Major topic |
| GPI-Linked Proteins | Major topic |
| Mutation | Major topic |
| Neoplasms | Major topic |
| Binding Sites | |
| Cell Line, Tumor | |
| Cloning, Molecular | |
| Humans | |
| Mesothelin | |
| Protein Binding |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| ZIA BC011652 | Intramural NIH HHS | United States | ZIABC011652 | PubMed and NIH |
Source NIH RePORTER
References10
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 31676721 | Mesothelin Enhances Tumor Vascularity in Newly Forming Pancreatic Peritoneal Metastases. | Mol Cancer Res | 2020 | https://conductscience.org/library/papers/31676721 | PubMed |
| 2 | 22351743 | Mesothelin-targeted agents in clinical trials and in preclinical development. | Mol Cancer Ther | 2012 | https://conductscience.org/library/papers/22351743 | PubMed |
| 3 | 27863199 | Mesothelin Immunotherapy for Cancer: Ready for Prime Time? | J Clin Oncol | 2016 | https://conductscience.org/library/papers/27863199 | PubMed |
| 4 | 7690548 | A mutation of furin causes the lack of precursor-processing activity in human colon carcinoma LoVo cells. | Biochem Biophys Res Commun | 1993 | https://conductscience.org/library/papers/7690548 | PubMed |
| 5 | 26503962 | Mesothelin-Targeted CARs: Driving T Cells to Solid Tumors. | Cancer Discov | 2016 | https://conductscience.org/library/papers/26503962 | PubMed |
| 6 | 30370397 | Megakaryocyte Potentiating Factor as a Predictive Biomarker for Therapies Against Malignant Mesothelioma. | JCO Precis Oncol | 2018 | https://conductscience.org/library/papers/30370397 | PubMed |
| 7 | 31463062 | Mesothelin as a biomarker for targeted therapy. | Biomark Res | 2019 | https://conductscience.org/library/papers/31463062 | PubMed |
| 8 | 1905715 | Arg-X-Lys/Arg-Arg motif as a signal for precursor cleavage catalyzed by furin within the constitutive secretory pathway. | J Biol Chem | 1991 | https://conductscience.org/library/papers/1905715 | PubMed |
| 9 | 8552591 | Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. | Proc Natl Acad Sci U S A | 1996 | https://conductscience.org/library/papers/8552591 | PubMed |
| 10 | 8150545 | Molecular cloning and expression of a cDNA encoding a protein detected by the K1 antibody from an ovarian carcinoma (OVCAR-3) cell line. | Int J Cancer | 1994 | https://conductscience.org/library/papers/8150545 | PubMed |
Cited by6
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 6 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42591971 | Conformational epitope engagement by anti-MSLN ADC RC88 confers resistance to soluble mesothelin. | Antib Ther | 2026 | https://conductscience.org/library/papers/42591971 | PubMed |
| 41994562 | Mesothelin biology and the evolving landscape of targeted immunotherapy. | Mol Ther Oncol | 2026 | https://conductscience.org/library/papers/41994562 | PubMed |
| 41335396 | Decoding the role of mesothelin in tumor dynamics and targeted treatment innovations. | Mol Biomed | 2025 | https://conductscience.org/library/papers/41335396 | PubMed |
| 40227616 | Mesothelin as a Signal Pathways and Epigenetic Target in Cancer Therapy. | Cancers (Basel) | 2025 | https://conductscience.org/library/papers/40227616 | PubMed |
| 35523008 | Low serum mesothelin in pancreatic cancer patients results from retention of shed mesothelin in the tumor microenvironment. | Transl Oncol | 2022 | https://conductscience.org/library/papers/35523008 | PubMed |
| 35326701 | Mesothelin: An Immunotherapeutic Target beyond Solid Tumors. | Cancers (Basel) | 2022 | https://conductscience.org/library/papers/35326701 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| FURIN | 5045 | PubTator's text mining | https://conductscience.org/library/genes/5045 | NCBI Gene |
| MSLN | 10232 | PubTator's text mining | https://conductscience.org/library/genes/10232 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/33476708
GET https://conductscience.org/api/papers/v1/33476708/authors